Avidity Biosciences (RNA) announced that the Japan Ministry of Health, Labour and Welfare has granted Orphan Drug designation to delpacibart etedesiran for the treatment of myotonic dystrophy type 1, an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies. Del-desiran is the first investigational treatment for DM1 to receive Orphan Drug designation in Japan. Del-desiran has also received Breakthrough Therapy, Orphan Drug and Fast Track designations by the U.S. FDA and Orphan designation by the European Medicines Agency.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences’ Promising Progress in FORTITUDE Study Boosts Buy Rating
- Avidity Biosciences Positioned for Market Leadership with Strategic Advancements in Dystrophy Programs
- Biotech stocks slide as Marks resignation seen being negative for sector
- Marks resignation ‘not good’ for biotech sector, says RBC
- Avidity Biosciences completes enrollment in Phase 1/2 Fortitude trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue